Aduro Biotech Inc

Aduro Biotech — Merger or Acquisition (June 2020)

16 slides from Aduro Biotech's merger presentation, Jun 2, 2020

  1. Slide 1: Developing Precision Medicines for Kidney Diseases: Merger Announcement

    Developing Precision Medicines for Kidney Diseases Merger Announcement June 2, 2020 Exhibit 99.2

  2. Slide 2: Note Regarding Forward-Looking Statements

    Note Regarding Forward-Looking Statements Certain of the statements made in this presentation are forward looking for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those relating to the benefits of the merger, future management and the boar

  3. Slide 3: Transformative & Synergistic Transaction for Aduro

    Transformative & Synergistic Transaction for Aduro Underwent strategic reset in Jan 2019 and corporate restructuring in Jan 2020 to reduce OpEx and extend cash position into 2023 Over the last ~12 months, explored strategic alternatives that would provide value to shareholders With recent increased

  4. Slide 4: Chinook – Precision Medicines for Kidney Diseases

    Chinook – Precision Medicines for Kidney Diseases Large, underserved markets Building a pipeline of targeted approaches and precision medicines to potentially treat kidney diseases Synergy between Chinook’s and Aduro’s key programs Multiple programs expected to be in clinical development in 2021 Sea

  5. Slide 5: The Time is Now for Kidney Disease Drug Development

    The Time is Now for Kidney Disease Drug Development Emerging patient stratification approaches and translational platforms Causal mutations, biomarkers, single-cell sequencing, organoid / podocyte systems Underserved market with >$100B of annual healthcare costs in U.S. Few new drugs approved in pas

  6. Slide 6: Focused Pipeline Targeting Kidney Diseases

    Focused Pipeline Targeting Kidney Diseases Program Indication Target Validation Lead Optimization IND-Enabling Phase 1 Phase 2 Phase 3 Atrasentan IgA Nephropathy (IgAN) Basket of glomerular diseases BION-1301 IgA Nephropathy (IgAN) CHK-336 Ultra-rare kidney disease Research Programs Other rare, seve

  7. Slide 7: Atrasentan

    Atrasentan Atrasentan is an investigational, potent, selective endothelin A (ETA) receptor antagonist previously developed by AbbVie Extensively studied with clinical data in >5,000 diabetic kidney disease patients Reduced proteinuria and preserved kidney function in clinical trials Well-characteriz

  8. Slide 8: SONAR Outcomes Supportive of Evaluation in IgA Nephropathy

    Proteinuria (UACR)* Kidney Function (eGFR Slope)* Proteinuria reduction at 6-9 months expected to be potential endpoint to seek accelerated approval in IgAN eGFR slope is potential confirmatory efficacy endpoint to seek full approval in IgAN Treatment effects on proteinuria predict stronger effects

  9. Slide 9: Two Clinical Programs in IgA Nephropathy

    Two Clinical Programs in IgA Nephropathy A progressive, chronic glomerular disease with limited treatment options Strategy to target key molecular drivers of progressive IgA Nephropathy in high-risk patients No approved treatments and limited options for high-risk patients Renin Angiotensin System i

  10. Slide 10: Experienced Leadership Team

    Experienced Leadership Team Executive Team Board Eric Dobmeier President and CEO Tom Frohlich Chief Business Officer Alan Glicklich, MD Chief Medical Officer Renata Oballa, PhD VP, Chemistry and Vancouver Site Head Andrew King, DVM, PhD Head of Renal Discovery and Translational Medicine Jerel Davis,

  11. Slide 11: Our Vision – Past, Present, and Future

    Our Vision – Past, Present, and Future Guiding R&D Principles: Focus on key pathways in kidney disease Design novel, target and differentiated molecules Utilize new and efficient translational approaches to speed R&D Execute clinical trials in defined patient populations with surrogate endpoints 202

  12. Slide 12: Transaction Summary

    Transaction Summary Structure of the transaction is a ~50:50 merger Strong financial position with ~$200M in cash, cash equivalents and marketable securities expected at closing Includes $25M in additional investment committed by Chinook’s existing investors Organizational and cost efficiencies in m

  13. Slide 13: Why Chinook?

    Why Chinook? Kidney disease is a large underserved market poised to be transformed by recent advances in the understanding of underlying diseases and new approaches to drug development Unique late-stage opportunity with lead asset atrasentan, and clinical program BION-1301 Building a differentiated

  14. Slide 14: Additional Information and Where to Find It

    Additional Information and Where to Find It Aduro plans to file a Registration Statement on Form S-4 containing a proxy statement/prospectus of Aduro and other documents concerning the proposed merger with the Securities and Exchange Commission (the “SEC”). BEFORE MAKING ANY VOTING DECISION, ADURO’S

  15. Slide 15: Participants in the Solicitation

    Participants in the Solicitation This document does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. Aduro and Chinook, and each of their respective directors, executive officers and certain employees may be deemed to be participants

  16. Slide 16: Developing Precision Medicines for Kidney Diseases: Merger Announcement

    Developing Precision Medicines for Kidney Diseases Merger Announcement June 2, 2020

Aduro Biotech — Merger or Acquisition (June 2020) on 6ix